Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Microenvironment dependent gene expression signatures in reprogrammed human colon normal and cancer cell lines

Authors: Egle Strainiene, Mindaugas Binkis, Silvija Urnikyte, Vaidotas Stankevicius, Ausra Sasnauskiene, Gabrielis Kundrotas, Andrius Kazlauskas, Kestutis Suziedelis

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Since the first evidence suggesting existence of stem-like cancer cells, the process of cells reprogramming to the stem cell state remains as an attractive tool for cancer stemness research. Current knowledge in the field of cancer stemness, indicates that the microenvironment is a fundamental regulator of cell behavior. With regard to this, we investigated the changes of genome wide gene expression in reprogrammed human colon normal epithelial CRL-1831 and colon carcinoma DLD1 cell lines grown under more physiologically relevant three-dimensional (3D) cell culture microenvironment compared to 2D monolayer.

Methods

Whole genome gene expression changes were evaluated in both cell lines cultured under 3D conditions over a 2D monolayer by gene expression microarray analysis. To evaluate the biological significance of gene expression changes, we performed pathway enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Gene network analysis was used to study relationships between differentially expressed genes (DEGs) in functional categories by the GeneMANIA Cytoscape toolkit.

Results

In total, we identified 3228 and 2654 differentially expressed genes (DEGs) for colon normal and cancer reprogrammed cell lines, respectively. Furthermore, the expression of 1097 genes was commonly regulated in both cell lines. KEGG enrichment analysis revealed that in total 129 and 101 pathways for iPSC-CRL-1831 and for CSC-DLD1, respectively, were enriched. Next, we grouped these pathways into three functional categories: cancer transformation/metastasis, cell interaction, and stemness. β-catenin (CTNNB1) was confirmed as a hub gene of all three functional categories.

Conclusions

Our present findings suggest common pathways between reprogrammed human colon normal epithelium (iPSC-CRL-1831) and adenocarcinoma (CSC-DLD1) cells grown under 3D microenvironment. In addition, we demonstrated that pathways important for cancer transformation and tumor metastatic activity are altered both in normal and cancer stem-like cells during the transfer from 2D to 3D culture conditions. Thus, we indicate the potential of cell culture models enriched in normal and cancer stem-like cells for the identification of new therapeutic targets in cancer treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci. 2003;100:3983–8.CrossRefPubMedPubMedCentral Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci. 2003;100:3983–8.CrossRefPubMedPubMedCentral
2.
go back to reference Tannishtha R, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.CrossRef Tannishtha R, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.CrossRef
3.
go back to reference Colak S, Zimberlin CD, Fessler E, Hogdal L, Prasetyanti PR, Grandela CM, et al. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ. 2014;21(7):1170.CrossRefPubMedPubMedCentral Colak S, Zimberlin CD, Fessler E, Hogdal L, Prasetyanti PR, Grandela CM, et al. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ. 2014;21(7):1170.CrossRefPubMedPubMedCentral
4.
go back to reference Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, et al. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006;66:9339–44.CrossRefPubMed Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, et al. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006;66:9339–44.CrossRefPubMed
5.
go back to reference Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells - old concepts, new insights. Cell Death Differ. 2008;15:947–58.CrossRefPubMed Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells - old concepts, new insights. Cell Death Differ. 2008;15:947–58.CrossRefPubMed
6.
go back to reference Islam F, Qiao B, Smith RA, Gopalan V, Lam AKY. Cancer stem cell: fundamental experimental pathological concepts and updates. Exp Mol Pathol. 2015;98:184–91.CrossRefPubMed Islam F, Qiao B, Smith RA, Gopalan V, Lam AKY. Cancer stem cell: fundamental experimental pathological concepts and updates. Exp Mol Pathol. 2015;98:184–91.CrossRefPubMed
7.
go back to reference Yoshida GJ, Saya H. Therapeutic strategies targeting cancer stem cells. Cancer Sci. 2016;107:5–11.CrossRefPubMed Yoshida GJ, Saya H. Therapeutic strategies targeting cancer stem cells. Cancer Sci. 2016;107:5–11.CrossRefPubMed
8.
go back to reference Nishi M, Sakai Y, Akutsu H, Nagashima Y, Quinn G, Masui S, et al. Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene. 2014;33:643–52.CrossRefPubMed Nishi M, Sakai Y, Akutsu H, Nagashima Y, Quinn G, Masui S, et al. Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene. 2014;33:643–52.CrossRefPubMed
9.
go back to reference Bai C, Yang M, Fan Z, Li S, Gao T, Fang Z. Associations of chemo- and radio-resistant phenotypes with the gap junction, adhesion and extracellular matrix in a three-dimensional culture model of soft sarcoma. J Exp Clin Cancer Res. 2015;34:1–10.CrossRef Bai C, Yang M, Fan Z, Li S, Gao T, Fang Z. Associations of chemo- and radio-resistant phenotypes with the gap junction, adhesion and extracellular matrix in a three-dimensional culture model of soft sarcoma. J Exp Clin Cancer Res. 2015;34:1–10.CrossRef
11.
go back to reference Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.CrossRefPubMed Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.CrossRefPubMed
12.
go back to reference Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci. 2010;107:40–5.CrossRefPubMed Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci. 2010;107:40–5.CrossRefPubMed
13.
go back to reference Miyazaki S, Yamamoto H, Miyoshi N, Wu X, Ogawa H, Uemura M, et al. A cancer reprogramming method using MicroRNAs as a novel therapeutic approach against colon cancer. Ann Surg Oncol. 2015;22(Suppl 3):1394–401.CrossRef Miyazaki S, Yamamoto H, Miyoshi N, Wu X, Ogawa H, Uemura M, et al. A cancer reprogramming method using MicroRNAs as a novel therapeutic approach against colon cancer. Ann Surg Oncol. 2015;22(Suppl 3):1394–401.CrossRef
14.
go back to reference Singovski G, Bernal C, Kuciak M, Kuciak M, et al. In vivo epigenetic reprogramming of primary human colon cancer cells enhances metastases. J Mol Cell Bio. 2016;8:157–73.CrossRef Singovski G, Bernal C, Kuciak M, Kuciak M, et al. In vivo epigenetic reprogramming of primary human colon cancer cells enhances metastases. J Mol Cell Bio. 2016;8:157–73.CrossRef
15.
go back to reference Chen L, Xiao Z, Meng Y, Zhao Y, Han J, Su G, et al. The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. Biomaterials. 2012;33:1437–44.CrossRefPubMed Chen L, Xiao Z, Meng Y, Zhao Y, Han J, Su G, et al. The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. Biomaterials. 2012;33:1437–44.CrossRefPubMed
17.
go back to reference Lu X, Zhao T. Clinical therapy using iPSCs: hopes and challenges. Genomics, Proteomics Bioinform. 2013;11:294–8.CrossRef Lu X, Zhao T. Clinical therapy using iPSCs: hopes and challenges. Genomics, Proteomics Bioinform. 2013;11:294–8.CrossRef
19.
go back to reference Carey BW, Markoulaki S, Hanna J, Saha K, Gao Q, Mitalipova M, et al. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci. 2009;106:157–62.CrossRefPubMed Carey BW, Markoulaki S, Hanna J, Saha K, Gao Q, Mitalipova M, et al. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci. 2009;106:157–62.CrossRefPubMed
20.
go back to reference Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, Hochedlinger K. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell. 2008;3:340–5.CrossRefPubMedPubMedCentral Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, Hochedlinger K. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell. 2008;3:340–5.CrossRefPubMedPubMedCentral
21.
go back to reference Chen W, Wong C, Vosburgh E, Levine AJ, Foran DJ, Xu EY. High-throughput image analysis of tumor spheroids: a user-friendly software application to measure the size of spheroids automatically and accurately. J Vis Exp. 2014;(89):1–10. Chen W, Wong C, Vosburgh E, Levine AJ, Foran DJ, Xu EY. High-throughput image analysis of tumor spheroids: a user-friendly software application to measure the size of spheroids automatically and accurately. J Vis Exp. 2014;(89):1–10.
22.
go back to reference Wang J, Duncan D, Shi Z, Zhang B. WEB-based GEne SeT AnaLysis toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013;41:77–83.CrossRef Wang J, Duncan D, Shi Z, Zhang B. WEB-based GEne SeT AnaLysis toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013;41:77–83.CrossRef
23.
go back to reference Montojo J, Zuberi K, Rodriguez H, Kazi F, Wright G, et al. GeneMANIA cytoscape plugin: fast gene function predictions on the desktop. Bioinformatics. 2010;26:2927–8.CrossRefPubMedPubMedCentral Montojo J, Zuberi K, Rodriguez H, Kazi F, Wright G, et al. GeneMANIA cytoscape plugin: fast gene function predictions on the desktop. Bioinformatics. 2010;26:2927–8.CrossRefPubMedPubMedCentral
24.
go back to reference Zschenker O, Streichert T, Hehlgans S, Cordes N. Genome-wide gene expression analysis in cancer cells reveals 3D growth to affect ECM and processes associated with cell adhesion but not DNA repair. PLoS One. 2012;7(4) Zschenker O, Streichert T, Hehlgans S, Cordes N. Genome-wide gene expression analysis in cancer cells reveals 3D growth to affect ECM and processes associated with cell adhesion but not DNA repair. PLoS One. 2012;7(4)
25.
go back to reference Gangadhara S, Smith C, Barrett-Lee P, Hiscox S. 3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response. BMC Cancer. 2016;16:345.CrossRefPubMedPubMedCentral Gangadhara S, Smith C, Barrett-Lee P, Hiscox S. 3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response. BMC Cancer. 2016;16:345.CrossRefPubMedPubMedCentral
26.
go back to reference Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279–90.CrossRefPubMed Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279–90.CrossRefPubMed
27.
go back to reference Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24:2899–908.CrossRefPubMed Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24:2899–908.CrossRefPubMed
28.
go back to reference Peng Y, Chen L, Li C, Lu W, Chen J. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem. 2001;276:40583–90.CrossRefPubMed Peng Y, Chen L, Li C, Lu W, Chen J. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem. 2001;276:40583–90.CrossRefPubMed
29.
go back to reference Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, Fojo T. P53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol. 2000;2:709–17.CrossRefPubMed Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, Fojo T. P53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol. 2000;2:709–17.CrossRefPubMed
30.
go back to reference Pick M, Ronen D, Yanuka O, Benvenisty N. Reprogramming of the MHC-I and its regulation by NFκB in human-induced pluripotent stem cells. Stem Cells. 2012;30:2700–8.CrossRefPubMed Pick M, Ronen D, Yanuka O, Benvenisty N. Reprogramming of the MHC-I and its regulation by NFκB in human-induced pluripotent stem cells. Stem Cells. 2012;30:2700–8.CrossRefPubMed
31.
go back to reference Carter SL, Centenera MM, Tilley WD, Selth LA, Butler LM. IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer. 2016;16:141.CrossRefPubMedPubMedCentral Carter SL, Centenera MM, Tilley WD, Selth LA, Butler LM. IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer. 2016;16:141.CrossRefPubMedPubMedCentral
33.
go back to reference Matsuzawa S, Reed JC. Siah-1, SIP, and Ebi collaborate in a novel pathway for β-catenin degradation linked to p53 responses. Mol Cell. 2001;7:915–26.CrossRefPubMed Matsuzawa S, Reed JC. Siah-1, SIP, and Ebi collaborate in a novel pathway for β-catenin degradation linked to p53 responses. Mol Cell. 2001;7:915–26.CrossRefPubMed
34.
go back to reference Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006;5:997–1014.CrossRefPubMed Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006;5:997–1014.CrossRefPubMed
35.
go back to reference Toshiyuki M, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293–9.CrossRef Toshiyuki M, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293–9.CrossRef
36.
go back to reference Lee GH, Yan C, Shin SJ, Hong SC, Ahn T, Moon A, et al. BAX inhibitor-1 enhances cancer metastasis by altering glucose metabolism and activating the sodium hydrogen exchanger: the alteration of mitochondrial function. Oncogene. 2010;29:2130–41.CrossRefPubMed Lee GH, Yan C, Shin SJ, Hong SC, Ahn T, Moon A, et al. BAX inhibitor-1 enhances cancer metastasis by altering glucose metabolism and activating the sodium hydrogen exchanger: the alteration of mitochondrial function. Oncogene. 2010;29:2130–41.CrossRefPubMed
37.
go back to reference Souček K, Gajdušková P, Brázdová M, Hýžd’alová M, Kočí L, Vydra D, et al. Fetal colon cell line FHC exhibits tumorigenic phenotype, complex karyotype, and TP53 gene mutation. Cancer Genet Cytogenet. 2010;197:107–16.CrossRefPubMed Souček K, Gajdušková P, Brázdová M, Hýžd’alová M, Kočí L, Vydra D, et al. Fetal colon cell line FHC exhibits tumorigenic phenotype, complex karyotype, and TP53 gene mutation. Cancer Genet Cytogenet. 2010;197:107–16.CrossRefPubMed
Metadata
Title
Microenvironment dependent gene expression signatures in reprogrammed human colon normal and cancer cell lines
Authors
Egle Strainiene
Mindaugas Binkis
Silvija Urnikyte
Vaidotas Stankevicius
Ausra Sasnauskiene
Gabrielis Kundrotas
Andrius Kazlauskas
Kestutis Suziedelis
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4145-8

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine